From traditional Chinese medicine to rational cancer therapy

Trends in Molecular Medicine

Volumn 13, Issue 8, 2007, Pages 353-361

  Efferth, Thomas ^a   Li, Paul C H ^b   Konkimalla, Venkata S Badireenath ^a   Kaina, Bernd ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b SIMON FRASER UNIVERSITY   (Canada)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIMOPHOL; AJMALICINE; ALLYL ISOTHIOCYANATE; ANDROGRAPHOLIDE; ARECOLINE; ARTESUNATE; ASIATICOSIDE; BERBERINE; CAFFEINE; CAMPTOTHECIN DERIVATIVE; CATECHIN; COCAINE; CODEINE; CURCUMIN; DESERPIDINE; DESLANOSIDE; DIGITOXIN; DIGOXIN; ESCIN; ESCULETIN; KAINIC ACID; MORPHINE; NATURAL PRODUCT; PAPAVERINE; SALICIN; SCOPOLAMINE; SENNOSIDE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

ALTERNATIVE MEDICINE; CANCER THERAPY; CHINESE MEDICINE; MEDICINAL PLANT; PHARMACOGNOSY; PHYTOCHEMISTRY; PHYTOTHERAPY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; PHARMACOGNOSY; WESTERN WORLD;

ARTESUNATE; VINCA;

EID: 34547179813     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.07.001     Document Type: Review

References (77)

1. Liu Y., et al. The Essential Book of Traditional Chinese Medicine: Theory, Clinical Practice (1988), Columbia University Press
2. Yin H. Fundamentals of Traditional Chinese Medicine (1992), CBT China Book Trading
3. Zhou J., et al. Traditional Chinese Medicine: Molecular Structures, Natural Sources and Applications. 2nd edn (2004), Wiley & Sons
4. Wink M. Plant breeding: importance of plant secondary metabolites for protection against pathogens and herbivores. Theor. Appl. Genet. 75 (1988) 225-233
5. Newman D.J., and Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70 (2007) 461-477
6. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6 (2006) 789-802
7. Giles G.I., and Sharma R.P. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem. 1 (2005) 383-394
8. Huang K.C. The Pharmacology of Chinese Herbs. 2nd edn (1999), CRC Press
9. Malmanche N., et al. The spindle assembly checkpoint: preventing chromosome mis-segregation during mitosis and meiosis. FEBS Lett. 580 (2006) 2888-2895
10. Duflos A., et al. Novel aspects of natural and modified vinca alkaloids. Curr. Med. Chem. Anticancer Agents 2 (2002) 55-70
11. Zhang C.H., et al. Enhanced paclitaxel production induced by the combination of elicitors in cell suspension cultures of Taxus chinensis. Biotechnol. Lett. 22 (2000) 1561-1564
12. Sarno S., et al. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol. Ther. 93 (2002) 159-168
13. Konkimalla V.B., et al. Diagnosis and therapy of oral squamous cell carcinoma. Expert Rev. Anticancer Ther. 7 (2007) 317-329
14. Sampedro Camarena F., et al. Telomerase and telomere dynamics in ageing and cancer: current status and future directions. Clin. Transl. Oncol. 9 (2007) 145-154
15. Zimmermann S., and Martens U.M. Telomeres and telomerase as targets for cancer therapy. Cell. Mol. Life Sci. 64 (2007) 906-921
16. Zhang F., et al. In vitro modulation of telomerase activity, telomere length and cell cycle in MKN45 cells by verbascoside. Planta Med. 68 (2002) 115-118
17. Guo Q.L., et al. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci. 78 (2006) 1238-1245
18. Kilarski W.W., and Bikfalvi A. Recent developments in tumor angiogenesis. Curr. Pharm. Biotechnol. 8 (2007) 3-9
19. Moreira I.S., et al. Vascular endothelial growth factor (VEGF) inhibition-a critical review. Anticancer Agents Med. Chem. 7 (2007) 223-245
20. Min J.K., et al. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res. 64 (2004) 644-651
21. Kok T.W., et al. The anti-angiogenic effect of sinomenine. Angiogenesis 8 (2005) 3-12
22. Shenai B.R., et al. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J. Biol. Chem. 275 (2000) 29000-29010
23. Krishna S., et al. Artemisinins: mechanisms of action and potential for resistance. Drug Resist. Updat. 7 (2004) 233-244
24. Bhisutthibhan J., and Meshnick S.R. Immunoprecipitation of [(3)H]dihydroartemisinin translationally controlled tumor protein (TCTP) adducts from Plasmodium falciparum-infected erythrocytes by using anti-TCTP antibodies. Antimicrob. Agents Chemother. 45 (2001) 2397-2399
25. Eckstein-Ludwig U., et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424 (2003) 957-961
26. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 8 (2005) 85-97
27. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 7 (2006) 407-421
28. Efferth T. Willmar schwabe award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med. 73 (2007) 299-309
29. Efferth T., et al. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 18 (2001) 767-773
30. Efferth T., et al. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 64 (2003) 382-394
31. Berger T.G., et al. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol. Rep. 14 (2005) 1599-1603
32. Douer D., and Tallman M.S. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol. 23 (2005) 2396-2410
33. Chang H.-M., and Pui-Hay But P. Pharmacology and Applications of Chinese Materia Medica (1986), Mainland Press
34. Fresno M., et al. Inhibition of translation in eukaryotic systems by harringtonine. Eur. J. Biochem. 72 (1977) 323-330
35. Efferth T., et al. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch. Pharmacol. 367 (2003) 56-67
36. Russo D., et al. MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukaemia 9 (1995) 513-516
37. Gillet, J.P. et al. Chemotherapy-induced resistance vy ATP-binding cassette transporter genes. Biochem. Biophys. Acta - Rev. Cancer (in press)
38. Kantarjian H.M., et al. Homoharringtonine: history, current research, and future direction. Cancer 92 (2001) 1591-1605
39. Miller W.H., et al. Mechanisms of action of arsenic trioxide. Cancer Res. 62 (2002) 3893-3903
40. Efferth T., and Kaina B. Microarray-based prediction of cytotoxicity of tumor cells to arsenic trioxide. Cancer Genomics Proteomics 1 (2004) 363-370
41. Shan H.B., et al. Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A. Anticancer Drugs 17 (2006) 905-911
42. Efferth T., et al. Molecular modes of action of cantharidin in tumor cells. Biochem. Pharmacol. 69 (2005) 811-818
43. Tang J.L., et al. Review of randomised clinical controlled trials of traditional Chinese medicine. BMJ 319 (1999) 160-161
44. Tang J.L. Research priorities in traditional Chinese medicine. BMJ 333 (2006) 391-394
45. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 12 (1994) 53-63
46. Soepenberg O., et al. Clinical studies of camptothecin and derivatives. Alkaloids Chem. Biol. 60 (2003) 1-50
47. Kingston D.G., and Newman D.J. Taxoids: cancer-fighting compounds from nature. Curr. Opin. Drug Discov. Devel. 10 (2007) 130-144
48. 3) in the treatment of acute promyelocytic leukaemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 (1997) 3354-3360
49. Soignet S.L., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukaemia. J. Clin. Oncol. 19 (2001) 3852-3860
50. Grem J.L., et al. Cephalotaxine esters: antileukemic advance or therapeutic failure? J. Natl. Cancer Inst. 80 (1988) 1095-1103
51. Luo C.Y., et al. Homoharringtonine: a new treatment option for myeloid leukaemia. Hematology 9 (2004) 259-270
52. Nortier J.L., et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342 (2000) 1686-1692
53. Arlt V.M., et al. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17 (2002) 265-277
54. Arlt V.M., et al. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int. J. Cancer 111 (2004) 977-980
55. Abelson P.H. Medicine from plants. Science 247 (1990) 513
56. Wink M. Bioprospecting: the search for bioactive lead structures from nature. In: Kayser O., and Quax W.J. (Eds). Medical Plant Biotechnology: From Basic Research to Industrial Applications Vol. 2 (2007), Wiley-VCH 97-116
57. Farnsworth N.R., et al. Medicinal plants in therapy. Bull. World Health Organ. 63 (1985) 965-981
58. Hsu H.Y., et al. Oriental Materia Medica (1986), Keats Publishing
59. Yen K.Y. An Illustrated Pharmacognosy. 2nd edn (1996), SMC Publishing
60. Warrell Jr. R.P., et al. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukaemia. J. Clin. Oncol. 3 (1985) 617-621
61. Tan C.T., et al. Phase I trial of homoharringtonine in children with refractory leukaemia. Cancer Treat. Rep. 71 (1987) 1245-1248
62. Feldman, E. et al. (1992a) Homoharringtonine is safe and effective for patients with acute myelogenous leukaemia. Leukaemia 6, 1185-1188
63. Feldman, E. et al. (1992b) Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukaemia. Leukaemia 6, 1189-1191
64. Bell B.A., et al. A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukaemia: a pediatric oncology group study. Med. Pediatr. Oncol. 37 (2001) 103-107
65. Levy V., et al. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br. J. Cancer 95 (2006) 253-259
66. Jin J., et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukaemia. Leukaemia 20 (2006) 1361-1367
67. Feldman E.J., et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukaemia. Leukaemia 10 (1996) 40-42
68. Kantarjian, H.M. et al. (2000b) Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukaemia. J. Clin. Oncol. 18, 3513-3521
69. O'Brien S., et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia in early chronic phase. Cancer 98 (2003) 888-893
70. Marin D., et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukaemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 103 (2005) 1850-1855
71. Kavanagh J.J., et al. Intermittent Iv homoharringtonine for the treatment of refractory epithelial carcinoma of the ovary: a phase II trial. Cancer Treat. Rep. 68 (1984) 1503-1504
72. Zhao T.P., et al. A clinical trial of homoharringtonine in the treatment of advanced breast cancer. Tumori 72 (1986) 395-398
73. Ajani J.A., et al. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. Cancer Treat. Rep. 70 (1986) 375-379
74. Runge-Morris M.A., et al. Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study. Invest. New Drugs 7 (1989) 269-273
75. Feun L.G., et al. Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. J. Neurooncol. 9 (1990) 159-163
76. Witte R.S., et al. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Invest. New Drugs 14 (1996) 409-413
77. Witte R.S., et al. A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. Invest. New Drugs 17 (1999) 173-177